22.6 C
New York
Saturday, June 13, 2026

Tag: SAFE

newssourceFORcompanyinformationcontent1marketreleases

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance (Nasdaq: AIFA) (“AIFA” or the “Company”) today provided a strategic update. Following the Company’s previously announced signing of agreements to acquire a controlling interest in HyalRoute Communication Group (“HyalRoute”) and advancement of the Hainan AIFA Silicon Photonics Supercomputing Center project, the Company is further accelerating project planning, policy coordination, financing arrangements, and cross-border resource integration around its dual-engine strategy of an “AI infrastructure network powered by optical technologies” and an “AI application services matrix.”

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

The Canadian Food Inspection Agency implements disease control measures to prevent spread of New World Screwworm

OTTAWA, ON, June 5, 2026 /CNW/ - Following a confirmed finding of New World screwworm in a calf in Texas, the Canadian Food Inspection...

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Driven by intensifying food safety requirements with the increased stringency of regulatory guidelines, a substantial and growing incidence of food fraud across global supply...

Message from the Minister of Health on World Food Safety Day 2026

OTTAWA, ON, June 5, 2026 /CNW/ - Food safety matters to every Canadian -- from our farms to our grocery stores to our kitchen...

Canadian Food Inspection Agency testing shows strong food safety in Canada

OTTAWA, ON, June 5, 2026 /CNW/ - The Canadian Food Inspection Agency (CFIA), Canada's largest science-based regulator, has published annual national testing and monitoring...

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

PPL Electric Utilities confirms continued support for rate case settlement following PUC approval

ALLENTOWN, Pa., June 5, 2026 /PRNewswire/ -- PPL Electric Utilities is pleased to report that, following the Pennsylvania Public Utility Commission's approval of its distribution...

GMI Cloud and Magna AI Partner to Expand Global Sovereign AI Infrastructure

Initial projects are planned in Malaysia, Belgium, and Romania, with additional locations under developmentSAN JOSE, Calif., June 5, 2026 /PRNewswire/ -- GMI Cloud, a leader...

Brayton Purcell LLP Highlights KQED Reporting on Federal Bill Affecting Artificial Stone Silicosis Claims

NOVATO, Calif., June 5, 2026 /PRNewswire/ -- Brayton Purcell LLP is bringing attention to a June 4, 2026 article by KQED News journalist Farida Jhabvala...

Centurion Acquisition Corp. Announces Postponement of Shareholders’ Meeting to Friday, June 12, 2026, and Extension of Redemption Request Deadline

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Centurion Acquisition Corp., a Cayman Islands exempted company, (“Centurion” or the “Company”) (Nasdaq: ALF) today announced that it intends to postpone its previously announced Extraordinary General Meeting of shareholders (the “Meeting”) from June 9, 2026, at 11:00 a.m. Eastern Time, to June 12, 2026 at 11:00 a.m. Eastern Time to allow Centurion additional time to engage with shareholders.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSAFE

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers